First, we found that circIGF2BP3 was preferentially expressed in NSCLC cells compared with immune cells (CD45+, CD3+, CD4+ and CD8+ cells) isolated from PBMCs of NSCLC patients. The gene discussed is CD4; the disease is non-small cell lung carcinoma.